Benzinga | Aug 4, 2021 07:04AM EDT

Boston Scientific Initiates Randomized Controlled Trial For The EkoSonic Endovascular System

Boston Scientific Corporation (NYSE:BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz comparing use of the EkoSonic(tm) Endovascular System (EKOS) in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk pulmonary embolism (PE).